Skip to content

Study · Randomized controlled trial · n = 375 · 2018

6 results

Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.

Wysham CH, Rosenstock J, Vetter ML, Dong F, Öhman P, Iqbal N

Diabetes, obesity & metabolism22 Aug 2017Cited by 25 (Europe PMC)

PMID28685973 (opens in a new tab)PMCIDPMC5724491 (opens in a new tab)DOI10.1111/dom.13056 (opens in a new tab)PepBankPUB-28685973
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In type 2 diabetes, exenatide QWS-AI reduced HbA1c more than exenatide twice daily.

    In plain wordsIn type 2 diabetes, once-weekly exenatide QWS-AI reduced HbA1c more than twice-daily exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c change
    Study

    n = 375

    Comparator
    Exenatide twice daily 10 μg
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2 mg once weekly · 28 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −1.4%
    QWS-AI
    HbA1c change
    −1%
    twice daily
    Least-squares mean difference
    −0.37%
    QWS-AI versus twice daily

    Source sentences

    Summary
    A total of 375 patients (mean HbA1c, 8.5% [69 mmol/mol]; body mass index, 33.2 kg/m2 ; diabetes duration, 8.5 years) received either exenatide QWS-AI (n = 229) or exenatide BID (n = 146); HbA1c was reduced by -1.4% and -1.0%, respectively (least-squares mean difference, -0.37%; P = .0072).
    1 context sentence
    Summary · context
    This randomized, open-label, controlled study in patients with type 2 diabetes using diet and exercise or taking stable oral glucose-lowering medication randomized patients 3:2 to either exenatide QWS-AI (2 mg) or exenatide BID (10 μg) for 28 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In type 2 diabetes, HbA1c target attainment was numerically higher with QWS-AI than twice-daily exenatide, without statistical significance.

    In plain wordsIn type 2 diabetes, target attainment was numerically higher with QWS-AI than twice-daily exenatide, without statistical significance.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeHbA1c below 7.0%
    Study

    n = 375

    Comparator
    Exenatide twice daily 10 μg
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2 mg once weekly · 28 weeksAs given in this study (human).

    Measurements

    HbA1c below 7.0%
    49.3%
    QWS-AI
    HbA1c below 7.0%
    43.2%
    twice daily

    Source sentences

    Summary
    More patients achieved HbA1c <7.0% with exenatide QWS-AI (49.3%) than with exenatide BID (43.2%; P = .225).
    1 context sentence
    Summary · context
    This randomized, open-label, controlled study in patients with type 2 diabetes using diet and exercise or taking stable oral glucose-lowering medication randomized patients 3:2 to either exenatide QWS-AI (2 mg) or exenatide BID (10 μg) for 28 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In type 2 diabetes, weight decreased in both exenatide groups without a significant between-group difference.

    In plain wordsIn type 2 diabetes, weight decreased in both exenatide groups without a significant difference between them.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeBody weight
    Study

    n = 375

    Comparator
    Exenatide twice daily 10 μg
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2 mg once weekly · 28 weeksAs given in this study (human).

    Source sentences

    Summary
    Body weight was reduced in both groups (P = .37 for difference).
    1 context sentence
    Summary · context
    This randomized, open-label, controlled study in patients with type 2 diabetes using diet and exercise or taking stable oral glucose-lowering medication randomized patients 3:2 to either exenatide QWS-AI (2 mg) or exenatide BID (10 μg) for 28 weeks.
  4. 04HumanRandomized controlled trialSafety outcome

    In type 2 diabetes, gastrointestinal adverse events were less frequent with QWS-AI than twice-daily exenatide.

    In plain wordsIn type 2 diabetes, gastrointestinal adverse events were less frequent with QWS-AI than twice-daily exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseGastrointestinal adverse events
    Study

    n = 375

    Comparator
    Exenatide twice daily 10 μg
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    2 mg once weekly · 28 weeksAs given in this study (human).

    Measurements

    Gastrointestinal adverse events
    22.7%
    QWS-AI
    Gastrointestinal adverse events
    35.6%
    twice daily

    Source sentences

    Summary
    Gastrointestinal adverse events (AEs) were reported in 22.7% (exenatide QWS-AI) and 35.6% (exenatide BID) of patients; fewer patients in the exenatide QWS-AI group withdrew because of AEs than in the exenatide BID group.
    1 context sentence
    Summary · context
    This randomized, open-label, controlled study in patients with type 2 diabetes using diet and exercise or taking stable oral glucose-lowering medication randomized patients 3:2 to either exenatide QWS-AI (2 mg) or exenatide BID (10 μg) for 28 weeks.
  5. 05HumanRandomized controlled trialSafety outcome

    In type 2 diabetes, fewer patients withdrew because of adverse events with QWS-AI than twice-daily exenatide.

    In plain wordsIn type 2 diabetes, fewer patients withdrew because of adverse events with QWS-AI than twice-daily exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseWithdrawal because of adverse events
    Study

    n = 375

    Comparator
    Exenatide twice daily 10 μg
    Outcome group
    Adverse events · Whole body
    Studied dose
    2 mg once weekly · 28 weeksAs given in this study (human).

    Source sentences

    Summary
    Gastrointestinal adverse events (AEs) were reported in 22.7% (exenatide QWS-AI) and 35.6% (exenatide BID) of patients; fewer patients in the exenatide QWS-AI group withdrew because of AEs than in the exenatide BID group.
    1 context sentence
    Summary · context
    This randomized, open-label, controlled study in patients with type 2 diabetes using diet and exercise or taking stable oral glucose-lowering medication randomized patients 3:2 to either exenatide QWS-AI (2 mg) or exenatide BID (10 μg) for 28 weeks.

Studies that did not test the peptide alone1

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 06HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialSafety outcome

    In the exenatide trial, minor hypoglycemia occurred most often with concomitant sulfonylurea use.

    In plain wordsIn the exenatide trial, minor low blood sugar occurred most often with concomitant sulfonylurea use.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseMinor hypoglycemia with sulfonylurea
    Study

    n: not reported in source

    Comparator
    Without concomitant sulfonylurea
    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    Minor hypoglycaemia occurred most often with concomitant sulfonylurea use.
    1 context sentence
    Summary · context
    This randomized, open-label, controlled study in patients with type 2 diabetes using diet and exercise or taking stable oral glucose-lowering medication randomized patients 3:2 to either exenatide QWS-AI (2 mg) or exenatide BID (10 μg) for 28 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01652716

Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes

AstraZenecan = 377Jan 2013 to Aug 2014

Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 3 Jul 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.